Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Investment analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Trevi Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.10) per share for the quarter, down from their prior estimate of ($0.09). HC Wainwright has a “Buy” rating and a $12.50 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at ($0.31) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01.

TRVI has been the topic of a number of other reports. Oppenheimer boosted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. B. Riley reaffirmed a “buy” rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reduced their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $17.56.

Trevi Therapeutics Trading Down 2.1 %

NASDAQ TRVI opened at $6.47 on Friday. The stock’s 50 day moving average is $4.60 and its 200 day moving average is $3.75. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The stock has a market cap of $497.32 million, a PE ratio of -14.70 and a beta of 0.90.

Hedge Funds Weigh In On Trevi Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after purchasing an additional 69,167 shares during the last quarter. Geode Capital Management LLC grew its position in Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after acquiring an additional 117,418 shares during the last quarter. Barclays PLC grew its position in Trevi Therapeutics by 180.8% in the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after acquiring an additional 61,317 shares during the last quarter. State Street Corp grew its position in Trevi Therapeutics by 5.9% in the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after acquiring an additional 53,051 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Insider Activity

In other news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 24.37% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.